- Home
- IAS vs MNKD Comparison
IAS vs MNKD Comparison
Compare IAS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- MNKD
- Stock Information
- Founded
- IAS 2009
- MNKD 1991
- Country
- IAS United States
- MNKD United States
- Employees
- IAS N/A
- MNKD N/A
- Industry
- IAS Computer Software: Programming Data Processing
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- IAS Technology
- MNKD Health Care
- Exchange
- IAS Nasdaq
- MNKD Nasdaq
- Market Cap
- IAS 1.7B
- MNKD 1.6B
- IPO Year
- IAS 2021
- MNKD 2004
- Fundamental
- Price
- IAS $6.52
- MNKD $4.54
- Analyst Decision
- IAS Buy
- MNKD Buy
- Analyst Count
- IAS 11
- MNKD 6
- Target Price
- IAS $14.35
- MNKD $8.92
- AVG Volume (30 Days)
- IAS 1.4M
- MNKD 2.2M
- Earning Date
- IAS 05-12-2025
- MNKD 05-07-2025
- Dividend Yield
- IAS N/A
- MNKD N/A
- EPS Growth
- IAS 475.01
- MNKD N/A
- EPS
- IAS 0.23
- MNKD 0.10
- Revenue
- IAS $530,101,000.00
- MNKD $285,504,000.00
- Revenue This Year
- IAS $13.20
- MNKD $14.23
- Revenue Next Year
- IAS $11.70
- MNKD $14.56
- P/E Ratio
- IAS $28.35
- MNKD $45.40
- Revenue Growth
- IAS 11.75
- MNKD 43.50
- 52 Week Low
- IAS $6.43
- MNKD $3.97
- 52 Week High
- IAS $13.62
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- IAS 28.41
- MNKD 28.12
- Support Level
- IAS $6.43
- MNKD $4.34
- Resistance Level
- IAS $6.96
- MNKD $4.72
- Average True Range (ATR)
- IAS 0.43
- MNKD 0.21
- MACD
- IAS -0.04
- MNKD -0.01
- Stochastic Oscillator
- IAS 10.93
- MNKD 27.03
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.